Targeted non-viral CRISPR-based in vivo gene editing (Sanofi/Scribe Therapeutics)

N/A

Report date: 2025/09/05 16:16:16

Base Information

Drug NameTargeted non-viral CRISPR-based in vivo gene editing (Sanofi/Scribe Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesScribe Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesScribe Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAnemia, Sickle Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A